Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
The Inaugural Hillel Panitch, MD Multiple Sclerosis Symposium
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Cognitive impairment in multiple sclerosis.
Sanofi MS drug nears green light after pass-the-parcel marathon
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
ALSUntangled No. 8: Low dose naltrexone for ALS.
Glatiramer acetate during early pregnancy: A prospective cohort study.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
Ofatumumab Dose-finding in RRMS Patients
HL-A antigens and multiple sclerosis.

Pages